TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 16, 2025 -- For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the addition of lenvatinib and pembrolizumab is associated with improved progression-free survival, according to a study published online Jan. 8 in The Lancet.
Masatoshi Kudo, M.D., from Kindai University in Osaka, Japan, and colleagues conducted a multicenter, randomized, double-blind, phase 3 study involving patients with unresectable, nonmetastatic hepatocellular carcinoma recruited from 137 global sites in 33 countries or regions. Participants were randomly assigned to receive TACE and either oral lenvatinib plus intravenous pembrolizumab or matched dual placebo (237 and 243 individuals, respectively). Participants were followed for a median of 25.6 months.
The researchers found that median progression-free survival was 14.6 and 10.0 months for TACE with lenvatinib plus pembrolizumab and TACE plus placebo, respectively (hazard ratio, 0.66; 95 percent confidence interval, 0.51 to 0.84; one-sided P = 0.0002). Twenty-nine and 34 percent of patients in the TACE with lenvatinib plus pembrolizumab and TACE plus placebo groups died, with 24-month overall survival rates of 75 and 69 percent, respectively (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.11; P = 0.087). Grade 3 or worse treatment-related adverse events occurred in 71 and 32 percent of participants in the group receiving TACE with lenvatinib plus pembrolizumab and the group receiving TACE plus placebo, respectively, with the most common being hypertension (24 versus 7 percent) and decreased platelet count (11 versus 6 percent).
"Based on these data, lenvatinib plus pembrolizumab combined with TACE could be a new treatment option for patients with unresectable, nonmetastatic hepatocellular carcinoma," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Eisai and Merck, which manufacture lenvatinib and pembrolizumab, respectively, and funded the trial.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis
THURSDAY, Dec. 5, 2024 -- Among patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAAs), a serum...
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
TUESDAY, Sept. 17, 2024 -- A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB)...
Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.